Antitumor activity of the novel pyridine derivative

Authors

DOI:

https://doi.org/10.3897/rrpharmacology.8.89997

Abstract

Introduction: The study aim was to explore a toxicological property and antitumor action of the novel pyridine deriv­ative LHT-17-19 in cell culture and on experimental models of lung cancer in mice.

Materials and methods: The study was performed on male and female ICR(CD-1), male BALB/c, male BALB/c nu/nu mice. Pyridine derivative (LHT-17-19) was studied as water-soluble pharmaceutical substance. Acute toxicity was evaluated in groups of 5 animals, and the results were analyzed by Finney. Antitumor and antimetastatic activity was studied in syngeneic and xenograft models of lung cancer in mice.

Results and discussion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with GOST 12.1.007–76. The substance demonstrated an antitumor and antimetastatic property in mice with syngeneic tumor Lewis lung carcinoma as well as on the heterotopic tumor model of non-small cell lung cancer in humanized animals.

Conclusion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with WHO recom­mendation. LHT-17-19 exerts antitumor and antimetastatic property on both syngeneic and patient-derived lung cancer xenograft murine models.

Graphical abstract:

Keywords:

pyridine derivative (LHT-17-19), lung cancer, acute toxicity, antitumor action, antimetastatic activity, mice

Author Contribution

V. Blinova Ekaterina, Sechenov University

Doctor Habil. of Medical Sciences, Professor of the Department of Operative Surgery and Clinical Anatomy.

Anna V. Epishkina, Sechenov University

Postgraduate student, Department of the Operative Surgery.

Oksana M. Tumutolova, Ogarev Mordovia State University

Candidate of Medical Sciences, Associate Professor, Department of Oncology.

Olga N. Deryabina, Ogarev Mordovia State University

Candidate of Medical Sciences, Associate Professor, Department of oncology.

Sofia Ya. Skachilova, All-Union Research Center for Safety of Biological Active Substances

Doctor Habil. of Chemical Sciences, Professor, Head of Pharmacology Department.

Mihail Yu. Kudriavtsev, Ogarev Mordovia State University

Postgraduate student, Department of Oncology.

Evgenia V. Shikh, Sechenov University

Doctor Habil. of Medical Sciences, Head of Clinical Pharmacology and Internal Disease Department.

Olga S. Vavilova, Sechenov University

Undergraduate student.

Yulia S. Gilevskaya, Sechenov University

Undergraduate student.

Gordey V. Brykin, Sechenov University

Undergraduate student.

Anna A. Makhrova, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Junior Researcher, Department of Molecular and Clinical Pharmacology.

Dmirty S. Blinov, All-Union Research Center for Safety of Biological Active Substances; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Doctor Habil. of Medical Sciences, Principal Researcher, Pharmacology Laboratory.

Downloads

Published

13-09-2022

How to Cite

Ekaterina VB, Epishkina AV, Tumutolova OM, Deryabina ON, Skachilova SY, Kudriavtsev MY, Shikh EV, Vavilova OS, Gilevskaya YS, Brykin GV, Makhrova AA, Blinov DS (2022) Antitumor activity of the novel pyridine derivative. Research Results in Pharmacology 8(3): 81–86. https://doi.org/10.3897/rrpharmacology.8.89997

Issue

Vol. 8 No. 3 (2022)

Section

Review article

Most read articles by the same author(s)